Skip to main content
SpringerLink
Log in

Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by thrombocytosis with megakaryocytic hyperplasia and thrombocytes are increased with abnormal functions. Discovery of the protein tyrosine kinase JAK2 V617F allele contributed to better understanding of the pathogenetic mechanisms of MPNs. Acquired single point mutation in the JAK2 V617F was determined approximately 50–60 % of patients with ET. In this study we aimed to investigate the relationship between JAK2 V617F gene mutation, hematologic, biochemical markers and the complications in the ET patients. A total of 268 patients diagnosed with ET and 219 of those studied for JAK2 gene mutation were followed at the hematology clinics of three major hospitals between 2008 and 2013 were screened retrospectively. Laboratory, clinical and hematologic parameters were compared for JAK2 V617F positive and JAK2 V617F negative patients with ET. 102 (46 %) patients were positive with the JAK2 V617F mutation. The complications were observed in 61 (28 %) patients and 38 (62 %) of them had JAK2 V617F mutation. The levels of white blood cells, neutrophil, basophil, red blood cells, hemoglobin, hematocrit, mean platelet volume, thrombocytes, eosinophil; urea, creatinine were significantly different in patients with the JAK2 V617F mutation (P < 0.05). Presence of the JAK2 V617F mutation supports the diagnosis of ET. It would be useful to investigate the JAK2 V617F mutation and the hematologic and biochemical markers at diagnosis with respect to consider the risk of developing complications and to take the precautions against these complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cervantes F (2011) Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2011:215–221. doi:10.1182/asheducation-2011.1.215

    Article  PubMed  Google Scholar 

  2. Karkucak M, Yakut T, Ozkocaman V, Ozkalemkas F, Ali R, Bayram M, Gorukmez O, Ocakoglu G (2012) Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. Mol Biol Rep 39:8663–8667

    Article  CAS  PubMed  Google Scholar 

  3. Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7(9):673

    Article  CAS  PubMed  Google Scholar 

  4. Mehtap Ö, Ateşoğlu EB, Tarkun P, Gönüllü E, Keski H, Topçu Y, Üzülmez N, Sünnetçi D, Hacıhanefioğlu A (2012) The association between gene polymorphisms and leukocytosis with thrombotic complications in patients with essential thrombocythemia and polycythemia vera. Turk J Hematol 29:162–169

    Article  CAS  Google Scholar 

  5. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T, Ematologia UO, Riuniti O (2007) Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 92:135–136

    Article  PubMed  Google Scholar 

  6. Antonioli E, Guglielmelli P, Pancrazzi A et al (2005) Clinical implications of the JAK2V617F mutation in essential thrombocythemia. Leukemia 19:1847–1849

    Article  CAS  PubMed  Google Scholar 

  7. Tefferi A, Thiele J, Vardiman JW (2009) The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 115(17):3842

    Article  CAS  PubMed  Google Scholar 

  8. Kralovics R, Passamonti F, Buser AS et al (2005) Gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–17790

    Article  CAS  PubMed  Google Scholar 

  9. Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061

    Article  CAS  PubMed  Google Scholar 

  10. James C, Ugo V, Le Couédic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434:1144–1148

    Article  CAS  PubMed  Google Scholar 

  11. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397

    Article  CAS  PubMed  Google Scholar 

  12. Langabeer SE, Ni Ainle F, Conneally E, Lawler M (2007) Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Ir J Med Sci 176:105–109

    Article  CAS  PubMed  Google Scholar 

  13. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945–1953

    Article  CAS  PubMed  Google Scholar 

  14. Basquiera AL, Soria NW, Ryser R et al (2009) Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology 14:323–330

    Article  CAS  PubMed  Google Scholar 

  15. Zhou J, Ye Y, Zeng S, Zhou Y, Mao Z, Song X, Ying B, Lu X, Jiang H, Wang L (2013) Impact of JAK2V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. PLoS ONE 8(2):e57856

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Shen YM, Chao HY, Zhang R et al (2009) Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders. J Int Med Res 37:37–46

    Article  CAS  PubMed  Google Scholar 

  17. Zhao R, Xing S, Li Z, Li Q (2005) Krantz SB, Zhao ZJ Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788–22792

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Benmoussa A, Dehbi H, Fehri S, Quessar A, Nadifi S (2011) JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects. Pathol Biol 59:e89–e92

    Article  CAS  PubMed  Google Scholar 

  19. Zhang SJ, Li WD, Song JH, Xu W, Qiu HX, Li JY (2007) The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis. Zhonghua Yi Xue Za Zhi 87:2109–2112

    CAS  PubMed  Google Scholar 

  20. Wong GC, Kam GL, Koay ES (2011) JAK2 mutations in Asian patients with essential thrombocythaemia. Intern Med J 41(2):191–196

    Article  PubMed  Google Scholar 

  21. Tefferi A, Lasho TL, Schwager SM et al (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera. Cancer 106:631–636

    Article  CAS  PubMed  Google Scholar 

  22. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prehal JT, Verstovsek S (2005) JAK2 mutation 1849G→T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome negative CML, and megakaryocytic leukemia. Blood 106:3370–3373

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Moliterno AR, Donna MW, Ophelia R, Spivak JL (2006) Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108:3913–3915

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A (2010) Is the absence of JAK2V617F mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients. Blood Transfus 8:21–27

    PubMed Central  PubMed  Google Scholar 

  25. Poopak B, Farshdousti Hagh M, Saki N, Elahi F, Rezvani H, Khosravipour G, Jahangirpour Ma, Bolouri S, Golkar T, Falah P (2013) JAK2 V617F mutation in Iranian patients with myeloproliferative neoplasms: clinical and laboratory findings. Turk. J Med Sci 43:347–353

    CAS  Google Scholar 

  26. Ha JS, Kim YK, Jung SI, Jung HR, Chung IS (2012) Correlations between janus kinas 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med 32:385–391

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Kerguelén Fuentes AE, Hernández-Maraver D, Lombardia L, Canales Albendea MA, Rodriguez de la Rúa A (2012) Clinical significance of the quantification of JAK2 V617F allele burden in classical Ph-negative myeloproliferative neoplasms. Med Clin (Barc) 139(9):373–378

    Article  Google Scholar 

  28. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Jou JM et al (2012) Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets 23(5):336–343

    Article  CAS  PubMed  Google Scholar 

  29. Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A et al (2011) JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood 118(9):2599–2601

    Article  CAS  PubMed  Google Scholar 

  30. Sokołowska B, Nowaczyńska A, Bykowska K, Chocholska S, Wejksza K et al (2011) JAK2 mutation status, hemostatic risk factors and thrombophilic factors inessential thrombocythemia (ET) patients. Folia Histochem Cytobiol 49:267–271

    Article  PubMed  Google Scholar 

  31. Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128(3):275

    Article  CAS  PubMed  Google Scholar 

  32. Schafer AI (2006) Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107(11):4214

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

We declare there is no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Bezmialem Vakif University Faculty of Medicine, Fatih, 34093, Istanbul, Turkey

    Güven Cetin, Tuba Ozkan, Seda Turgut, M. Ali Cikrikcioglu, Sevda Rabia Celik, Yahya Sekin & Cumali Karatoprak

  2. Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey

    M. Cem Ar

  3. Haseki Training and Research Hospital, Hematology Clinic, Fatih, Istanbul, Turkey

    Mesut Ayer

  4. Department of Biophysics, Trakya University Faculty of Medicine, 22030, Edirne, Turkey

    Ayhan Unlu

Authors
  1. Güven Cetin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tuba Ozkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seda Turgut
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Ali Cikrikcioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Cem Ar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mesut Ayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ayhan Unlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sevda Rabia Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yahya Sekin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Cumali Karatoprak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ayhan Unlu.

Additional information

Dr Güven Cetin, Dr M. Cem Ar and Dr Mesut Ayer are chiefs of hematology clinics of three major hospitals in Istanbul where patients were followed. Dr M. Ali Cikrikcioglu, Dr Cumali Karatoprak are responsible for statistical analysis in this study. Dr Ayhan Unlu is specialist of department of Biophysics and is responsible for JAK-2 mutations in this study. Dr Tuba Ozkan, Dr Seda Turgut, Dr Sevda Celik and Dr Yahya Sekin are assistant doctors of department of Internal Medicine.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cetin, G., Ozkan, T., Turgut, S. et al. Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis. Mol Biol Rep 41, 6737–6742 (2014). https://doi.org/10.1007/s11033-014-3559-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3559-x

Keywords

Search

Navigation